Over the past decade, BTKi have become increasingly used for treatment of hematologic malignancies and exert antiplatelet effects with a mechanism of action that is different than that of aspirin and P2Y12 inhibitors, agents commonly used in cardiovascular medicine. The gene discussed is P2RY12; the disease is hematologic disorder.